Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine/Attending Gastroenterologist
Yale University School of Medicine/PACT-Gastroenterology Center

Disclosure(s): Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant, Grant/Research Support; Merck and Co: Advisor/Consultant; SERES Therapeutics: Advisor/Consultant, Grant/Research Support; Takeda Pharmaceuticals: Advisor/Consultant

Poster(s):

• 236 - Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 522 - Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET